Skip Navigation Links
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention
Centers for Disease Control and Prevention CDC Home Search Health Topics A-Z

OD/ADS Technology Transfer Office
Technology Transfer Office
TTO Home About Us  | Technology | Forms | What's New | Contact Us

 

Sample Letter of Intent for a 

COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT

[Company Name and Address]

 

 

Dear ________________________:

It is my understanding that a cooperative research and development project between the parties referenced below is being considered. Accordingly, until the formal Collaborative Research and Development Agreement (CRADA) is reviewed by the Agency and approved by the Director, CDC Center, Institute, or Office (CIO), this Letter is offered to permit the joint research to commence.

It is acknowledged by the parties below that cooperative research pursuant to the Research Plan, attached as Appendix A, will be conducted informally by the CDC Principle Investigator and Collaborator pending formal approval of the CRADA. It is further acknowledged that patentable inventions may be made by CDC employees and employees of the Collaborator. Pursuant to its authority under the Federal Technology Transfer Act of 1986, CDC agrees that should this CRADA be approved, it will have retroactive effect to the date that the last party has executed this Letter for any inventions that may be made under this Research Plan. CDC further agrees that this CRADA also will have retroactive effect to the date that the last party has executed this Letter for confidentiality obligations specified in the PHS Model CRADA. The PHS Model CRADA provisions for the protection of proprietary information are incorporated by reference and are considered controlling. These provisions include, but are not limited to Articles 2.7 and 8.1_8.7. The PHS Model CRADA is attached as Appendix B.

You understand, however, that this letter is not a commitment on the part of either party to enter into a CRADA. Further, this Letter is effective for a term not to exceed six months. The six month term may be extended, provided the CRADA is under active negotiation and the collaborative research is continuing. Assuming that the necessary approvals are forthcoming, we look forward to a successful collaboration.

Sincerely,

 

Andrew Watkins, J.D., Ph.D.

Director, CDC Technology Transfer Office

 

AGREED AND ACCEPTED:

CDC Center, Institute, or Office CompanyName 

Name

Director, CIO

___________________ ___________________

Date Date 

Attachments

 

 

TTO Home | About Us | Technology | Forms | What's New | Contact Us

CDC Home | Search | Health Topics A-Z

This page last reviewed August 8, 2002
Centers for Disease Control and Prevention
Office of Director
Technology Transfer Office